DANIEL GENE CHONG M.D. NPI 1942462601

NPI Details

Daniel Gene Chong, M.D. is a hematology and oncology internal medicine in Fairfax, VA with 17 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Daniel Gene Chong, M.D. NPI is 1942462601. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE
Graduation Year:2008

The provider's business location address is:

3700 JOSEPH SIEWICK DR STE 408
FAIRFAX, VA
ZIP 22033-745
Phone: (571) 350-8400
Fax: (703) 620-0952

The NPI 1942462601 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Nephelometry, test method using light (HCPCS:83883)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Protein measurement, serum (HCPCS:84165)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Unclassified drugs (HCPCS:J3490)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Uric acid level, blood (HCPCS:84550)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Magnesium level (HCPCS:83735)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Folic acid level, serum (HCPCS:82746)
• Injection of drug or substance into vein (HCPCS:96374)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Aspiration of bone marrow sample for diagnosis (HCPCS:38220)

The enumeration date for this NPI number is 6/25/2008 and was last updated on 3/10/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.